Breast cancer is the second leading cause of cancer-related death in women, 1.7 million new cases of breast cancer occur each year, with a global economic burden estimated at US$88 billion. A woman’s chance of survival is significantly increased with early detection. Women with dense breast tissue have a 4 to 6 times increased risk of breast cancer compared to women with non-dense tissue. Unfortunately, the group at highest risk of cancer is also the group for which mammography is least effective. Mammography has major limitations and fails to detect approximately half of cancers in women with dense breast tissue.
Tiro Medical, a multidisciplinary shareholder group, has developed a breast imaging device (the OE scan) based on the use of Optical Elastography and Digital Physiological Analysis. The Tiro solution has higher contrast ratio in dense tissues allowing for improved diagnosis in this population, uses zero radiation so is not limited by age and can be used in any condition (pregnancy, specific illness etc.) and has zero pain leading to better compliance.